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Abstract
Background: Immunosuppressive agents used to treat inflammatory bowel disease (IBD) can 
increase the risk for infections, several of which are preventable through vaccination. Our study 
aimed to describe vaccine utilization by immunosuppression status, examine reasons for vaccine 
refusal, and identify characteristics associated with lack of influenza vaccination in IBD patients.
Methods: We administered an online survey between Feb 2012 and April 2012 to an internet-
based cohort of IBD patients in the Crohn’s and Colitis Foundation of America Partners program.
Results: During this time, 958 individuals completed the survey. The median age was 45, 72.8% 
were female, and 62.0 % had Crohn’s disease. Self-reported vaccination rates were low. Those on 
immunosuppression (n=514) were more likely to be counseled to avoid live vaccines (p<0.01). 
However, counseling rates were low (3.5% to 19.1% for various live vaccines). Among the 776 
individuals who received the influenza vaccine, maintaining health (74.1%), importance of 
prevention (66.1%), and provider recommendation (38%) were the most frequently cited 
motivations. Factors associated with lack of influenza vaccine included lower education level 
(p=0.01), younger age (p=0.02) and no chronic immunosuppression use (p<0.01). 570 (59.5%) 
individuals thought that patients were responsible for keeping track of their vaccines, while 428 
(44.7%) placed responsibility on their gastroenterologist (GI) and 595 (62.1%) on their primary 
care physician (PCP).
Conclusions: Vaccine utilization remains sub-optimal in IBD patients. Educational 
interventions may increase vaccination rates by clarifying misconceptions. GIs can play a more 
active role in health care maintenance in IBD patients by counseling patients on which vaccines to 
receive or avoid.
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Current therapy for inflammatory bowel disease (IBD) patients often involves agents that 
suppress the immune system. These treatments put patients at an increased risk for 
developing infections, of which several are potentially preventable through timely 
vaccination. Prior work has shown a significantly increased risk of pneumonia among IBD 
patients, highlighting the importance of primary prevention via vaccination.4 Unfortunately, 
despite guidelines specifying appropriate vaccination strategies in immunosuppressed 
patients, 1, 2 many IBD patients are not being vaccinated appropriately. For example, in one 
tertiary care center study of vaccination efforts in IBD patients, only 28% received annual 
influenza vaccine and only 9% received pneumococcal vaccine.3 Reported barriers to 
vaccination include a lack of awareness and concern for side effects by patients, suggesting 
that providers may not appropriately educate patients as to the importance of these vaccines.
Similarly, gastroenterologist knowledge of the appropriate immunizations for the IBD 
patient is poor.5, 6 A recent survey demonstrated that nearly one third of gastroenterologists 
would mistakenly recommend live vaccines to their immunosuppressed IBD patients5. Up to 
one half of the gastroenterologists in this survey would incorrectly withhold inactivated 
vaccines to their immunocompromised patients. Additionally, nearly one third of 
gastroenterologists would avoid live vaccinations in their immunocompetent patients despite 
guideline recommendations that they can be safely administered, placing this patient group 
at a particularly high risk given the potential need for immunosuppression to treat their IBD 
at a later date. Given that physician knowledge is poor, it should therefore come as no 
surprise that patients are not being adequately immunized. Previous studies have 
emphasized the importance of provider recommendations in patient decisions to receive 
vaccines 7, 8. However, if providers lack knowledge about and confidence in which 
vaccinations to recommend, patients will then be less likely to receive the appropriate 
vaccines.
While smaller surveys of patients have been done3, to date there have been no large studies 
examining vaccination perceptions among a diverse IBD population in the United States. 
Furthermore, little is known about the reasons behind suboptimal rates of vaccination in IBD 
patients and whether patient preferences, patient-provider interactions, or systems issues 
(e.g.access to care, insurance, cost) are the main driving force. The aims of our study were 
to: 1) describe vaccine utilization in individuals with IBD and whether this differs by 
immunosuppression status; 2) examine both the motivation and rationale for vaccine 
acceptance and refusal among individuals with IBD; and 3) identify characteristics 
associated with lack of influenza vaccination.
Methods
Crohn’s and Colitis Foundation of America Partners
We used an internet-based cohort, the Crohn’s and Colitis Foundation of America (CCFA) 
Partners, to investigate vaccine beliefs in individuals with self-reported inflammatory bowel 
disease (IBD). CCFA Partners follows individuals with self-reported IBD who were 
recruited from CCFA email lists and other social media outlets. Participants complete 
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baseline and semi-annual follow-up surveys regarding demographics, disease location and 
activity, medication use, prevention activities (such as screenings or vaccines) and quality of 
life measurements. Further details of the cohort and baseline characteristics of the 
population are described elsewhere9.
Vaccine beliefs survey
We developed a 7 question close-ended survey instrument about vaccine utilization and 
beliefs, including motivating factors and concerns (see Appendix 1). The survey was 
developed based on a prior survey study used to describe gastroenterologists behavior in 
prescribing vaccines5 and was piloted in five IBD patients seen in our gastroenterology 
office at Boston Medical Center. The vaccine beliefs survey module was then administered 
in all online follow up surveys to the CCFA Partners cohort that were completed between 
February 16, 2012 and April 24, 2012 until a total of at least 950 responses was obtained. 
This number was based on a power calculation to estimate the number of individuals 
required to be able to detect a 10% difference in influenza receipt amongst those on 
immunosuppresssion as compared to those not on immunosuppression.
Data Collection and Management
The data were collected entirely in a Web-based format, which allowed for real-time 
implementation of range and consistency checks. Therefore, missing data were minimized at 
point of entry. The data management system has previously been described9. The Web 
forms were accessible from any computer running a modern Internet browser with an active 
connection to the Internet; no special software was required. Data on demographics, disease 
type, medications and vaccination status were extracted from CCFA Partners core data for 
survey respondents
Statistical Analysis
All outcomes and characteristics were stratified by the primary categories of interest: use of 
immunosuppression and influenza vaccination within the prior 12 months. Descriptive 
statistics were used to characterize the population, including proportions, means and 
standard deviations (SD) for normally distributed variables, and medians and interquartile 
ranges (IQR) for nonparametic data. Chi-square, Fisher’s exact, Wilcoxon rank sum, 
Student’s t-test and oneway ANOVA were used to compare characteristics and beliefs by 
use of immunosuppression and by influenza vaccination. STATA version 10.0 (College 
Station, TX) was used for all analyses and p values less than 0.05 were considered 
statistically significant. The study protocol was approved by the Institutional Review Board 
at the University of North Carolina at Chapel Hill.
Results
A total of 958 persons completed the vaccine survey. Those persons (n=33) who did not 
provide information on whether they had received vaccinations were excluded from the 
study. The median age of the surveyed group was 45 (IQ 31-57), 72.8% were female, and 
62% had Crohn’s disease (CD). Table 1 summarizes the characteristics of the study 
population. No differences in age, sex, race, ethnicity, education, IBD type, and rating of 
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general health were detected between vaccine survey participants compared to those 
participants in the CCFA cohort who were not given the vaccine survey.
Overall, self-reported vaccination rates were low (Figure 1). As noted in the vaccine module 
(Appendix 1), we used terminology that patients would understand and thus did not ask 
about specific brands or sub-types of vaccines, such as differentiating between the 
pneumococcal conjugate vaccine (PCV13) and the pneumococcal 23-valent polysaccharide 
vaccine (PPVSV23). Of the inactivated vaccines, the influenza vaccine (received in 2011, 
just prior to the survey) was most commonly received (81.5% of the population). Only 
47.7% reported receiving the hepatitis B vaccine, 42.6% the pneumococcal vaccine, and 
34.1% the hepatitis A vaccine. Among women under age 27, 50% reported that they had 
received the human papilloma virus (HPV) vaccine (vaccine only approved in women at the 
time of the survey). Of the live vaccines, 33.3% of those over age 60 recalled receiving the 
herpes zoster vaccine.
When asked who shared responsibility for vaccination efforts, 570 (59.5%) subjects thought 
that they (patients) were responsible for keeping track of their vaccines, while 428 (44.7%) 
placed the responsibility on their gastroenterologist and 595 (62.1%) on their primary care 
provider. Only 430 subjects (44.9%) recalled that their gastroenterologists had previously 
taken a vaccination history. Those patients on immunosuppression were significantly more 
likely to be counseled on avoidance of live vaccines (p<0.01). However, counseling rates as 
a whole were low, ranging from 3.5% to 19.1% for the various live vaccines (Table 2). 
There were no differences noted in the concerns about the vaccines effectiveness or the 
possible side effects of the vaccines by immunosuppression status.
Among the 776 individuals who received the influenza vaccine, maintaining health (74.1%), 
importance of prevention (66.1%), and provider recommendation (38%) were the most 
frequently cited motivations. Patients receiving the influenza vaccine were more likely to 
have a primary care provider than those who did not receive the vaccine (91.2% vs. 81.8%, 
p<0.01). There was also a higher rate of immunosupression use among those receiving the 
influenza vaccine when compared to those who did not receive the vaccine (55.8% vs. 
44.9%, p<0.01). Age, gender, and smoking status did not differ by vaccination status.
Those not receiving the influenza vaccine (n=176) were significantly more concerned about 
side effects, effectiveness, and the worsening of their IBD by vaccines than those who 
received the influenza vaccine (p<0.01). Other factors associated with not receiving the 
influenza vaccine included lower education level (p=0.01), younger age (p=0.02) and 
absence of chronic immunosuppression use (p<0.01).
Discussion
Appropriate immunizations are an important component of routine preventive services in 
IBD patients. Immunosuppressive therapy puts patients at increased risk of developing 
infections which account for significant morbidity and mortality in IBD patients10, 11. 
Active CD has also been shown to increase the risk for serious infections,10 further 
supporting the crucial need for appropriate immunization to avoid potentially preventable 
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infections. A recent study demonstrated that patients with IBD are at increased risk for 
pneumonia, particularly among patients on corticosteroids and narcotics.4 Varicella 
infection12 and herpes zoster13 infection have also been found to be increased in 
immunosuppressed IBD patients, particularly in those on corticosteroids, thiopurines, anti-
TNF agents, or combination immunosuppression. As demonstrated in this large, cross-
sectional survey of IBD patients, however, vaccination rates for these preventable diseases 
remain suboptimal despite over a decade of data confirming that IBD patients are at an 
increased risk of vaccine preventable diseases. Patients who were most likely to receive the 
influenza vaccine were most concerned about maintaining their health, preventing disease, 
and followed their provider’s recommendations. In contrast, patients who did not receive the 
vaccine had misconceptions about possible side effects of the vaccine or worsening of their 
IBD after vaccination. “Provider recommendation” was one of the most frequently cited 
motivations for receiving the influenza vaccine, the most commonly received vaccine in this 
study. Yet, only half of the patients recalled being asked by their gastroenterologist about 
their vaccination history.
Several prior studies have demonstrated that provider recommendations are a strong 
predictor for receipt of preventative health services including vaccination and cancer 
screening14-16. Unfortunately, primary care clinicians are uncomfortable managing routine 
health maintenance issues in their IBD patients. For example, only 30% of family medicine 
doctors felt comfortable coordinating vaccinations for the immunosuppressed IBD patient17. 
As primary care physicians may not adequately prescribe vaccines for immunosuppressed 
IBD patients, gastroenterologists should obtain a vaccine history and should accept the 
responsibility of either offering vaccinations in their office or providing recommendations to 
the primary care clinician for the appropriate vaccines to be adminsitered.18, 19 
Immunization status should be detailed during the first office visit and the required vaccines, 
especially the live attenuated vaccines, should be administered during the period before 
immunosuppressive medication is started. In one study, the influenza vaccine was offered 
and administered to eligible immunosuppressed IBD patients during their IBD office visit. 
Vaccination rates for influenza increased in this group from 54% to 81% suggesting that 
easy access to vaccines can also improve uptake.23 In our study, rates of influenza vaccine 
were 81.5% which is higher than that reported in previous studies. This suggests that 
awareness for vaccinations in IBD patients has improved over time, possibly due to 
increased media focus, interventions in GI offices, and reminders for all patients regardless 
of IBD status.
Patients on immunosuppressive medications were more likely to be counseled to avoid live 
vaccines, but counseling rates overall were low, again suggesting that physicians are missing 
the opportunity to prevent potential infectious complications in their patients. Since provider 
recommendation was found to be an important reason why patients chose to receive a 
vaccine, spending time educating patients on the importance of vaccines during an office 
visit either through a face to face discussion with a member of the GI team or through a 
handout may be beneficial. Side effects, effectiveness, and worsening of their IBD by 
vaccines were cited as the biggest concerns among the 176 patients who did not receive the 
influenza vaccine. Although immunologic response to vaccination appears to be decreased 
in immunosuppressed patients, there is no convincing evidence to suggest that immunization 
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will lead to an exacerbation of IBD activity.1 These concerns emphasize the importance of 
intensive educational efforts, for both provider and patient, in order to ensure that 
misconceptions are clarified and that patients receive the appropriate vaccinations. It is 
important to remember that based on our results, in those patients who are younger or less 
educated, additional time discussing these misconceptions might increase vaccination rates.
The strengths of this study include the large number of surveyed participants who were 
geographically diverse and represent many different clinical practices. Additionally, we 
were able to obtain detailed information on demographics, disease status, and medication 
use. The anonymous nature of the survey may have allowed participants to honestly provide 
their views on recommended routine vaccinations.
The main limitation of this cross-sectional study was in its design as a self-administered 
electronic survey. Methods of recruitment included an interest in participating, requirement 
for the English language, and the technology to join the cohort. The sample therefore may 
not necessarily represent the US IBD population as a whole. In addition, all of the data 
collected were based on participant self-reporting rather than on audit of medical records. 
Reassuringly, a previous validation study has been completed on a subset of the study 
cohort. Within this group on whom physicians confirmed diagnoses via medical record 
review, 94% of patients have a diagnosis of IBD Additionally, other previously established 
associations were confirmed within this cohort, supporting the validity of this patient 
reported data. Vaccine utilization was also obtained via self-report which may be subject to 
under or over reporting. Because billing records would not contain information on 
vaccination through employers or at local pharmacies where no insurance billing occurs, 
self-report may actually be the best means at obtaining vaccine utilization information. 
Other studies of self-report of vaccine utilization have shown a high concordance between 
the medical records and patients’ self-reported vaccine exposure to influenza, pneumococcal 
and HPV vaccines.20, 21 However, because vaccines were self-reported, no distinction was 
made about which particular vaccine the patients had received. Another limitation of our 
study is that it did not include a pediatric/adolescent IBD subset, who have also been shown 
to have suboptimal immunization rates.22 We did find that the younger patients in this 
cohort were less likely to have received the influenza vaccine suggesting that we do need to 
improve our vaccination rates in our younger patients as well. Lastly, we could not control 
for other potential confounders in vaccination utilization such as other co-morbidites (e.g. 
asthma) or occupation since we did not have this information.
In summary, our study confirms prior reports that patients with IBD are not receiving 
counseling regarding appropriate vaccinations and are inadequately vaccinated. Importantly, 
we were also able to determine patient perceptions and rationales for avoiding vaccination, 
in order to target future educational efforts. The findings of this study thus serves as an 
important reminder that we need to continue to improve the education of this high risk 
population of patients and their primary health care providers regarding the safety of 
administering vaccinations while remembering to address possible misconceptions are 
paramount in increasing vaccine rates. Since physician recommendation for vaccinations is a 
primary motivation among IBD patients, future efforts should focus on education and 
systems-based practices to improve vaccination efforts. As a community of 
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gastroenterologists, we should play a more active role in the health care maintenance in our 
IBD patients.
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Appendix 1 Patient Vaccine Survey
1. Who do you think is responsible for determining which vaccinations you should 
receive? (Check all that apply.)
□ Your gastroenterologist
□ Your primary care physician
□ I am responsible
□ Other ________________




3. Has your gastroenterologist told you that you need to avoid certain vaccines?
○ Yes
○ No (skips to 5)
○ Don’t know (skips to 5)
4. Which of the following vaccines have you been told to avoid? (Check all that 
apply.)
□ Hepatitis




□ Varicella (chicken pox)
□ MMR (measles, mumps, rubella)
□ Tetanus
□ Other ________________
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5. (If the respondent said YES to Q4440 at FOLLOW-UP): You told us that you 
received a flu shot this year. What motivated you to get your influenza vaccine (flu 
shot)? (Check all that apply.)
□ It is important for my health.
□ I want to do what my doctor recommends.
□ I like doing things that prevent future health problems.
□ It is readily available at my doctor’s office.
□ Other __________
6. The following questions will ask you to rate 3 possible concerns about vaccines, 
please answer the questions in general (not focusing upon a specific vaccine):
7. Which of the following might influence your decision to avoid a vaccine? (Check 
all that apply.)
□ I don’t think vaccines are important.
□ I do not know where to get the vaccines recommended to me.
□ Vaccines are too expensive.
Since <DATE LAST STARTED/CONSENTED TO A SURVEY>did you receive 
a flu shot or flu mist (nasal vaccine)?
○ Yes [skips to Q4300]
○ No
○ Don’t know [skips to Q4300]
(Q4480) Why did you not receive a flu shot? (Check all that apply.)
□ Never offered flu shot
□ Allergy to eggs/vaccines
□ Did not think I needed it
□ Too expensive
□ Vaccine not available
□ Too busy/forgot
□ Concerned about side effects from the vaccine
□ Concerned that the vaccine would worsen my IBD
□ My doctor advised against a flu shot
□ Other reason ____________________
□ Don’t know
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(Q4300) Have you had any other new vaccines since <DATE CONSENT/START 
LAST SURVEY>?
○ Yes
○ No [skips to Q4520]
○ Don’t know [skips to Q4520]
Which of the following adult vaccines have you had since <DATE LAST 
STARTED/CONSENTED TO A SURVEY>:
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Table 1
Characteristics of the population of patients with inflammatory bowel disease in the CCFA Partners cohort 
who reported information on vaccine utilization and beliefs (n=958)
Characteristic N=958 % or median (IQR)
IBD type
 Crohn′s disease 594 62.0
 Ulcerative colitis 364 38.0
Age (median, IQR) 957 45 (31-57)
Sex (% female) 697 72.8
Primary care physician (% yes) 858 89.6
Education level
 Less than 12th grade 10 1.1
 High school graduate 67 7.3
 Some college 169 18.4
 College graduate 382 41.7
 Graduate school 289 31.5
Current smoker 40 4.2
Current medications (% yes)
 Antibiotics* 49 5.1
 5-ASA,** oral 542 56.8
 5-ASA, rectal 91 9.5
 Biologic^ 337 35.2
 Thiopurine% 248 26.0
 Methotrexate 33 3.5
 Calcineurin inhibitor# 3 0.3
 Corticosteroid, oral 101 10.6
 Corticosteroid, rectal 43 4.5
 Budesonide (oral) 40 4.2
Clinical trial medication 4 0.4












chronic immunosuppression defined as current use of biologic or immunomodulator (thiopurine, methotrexate, calcineurin inhibitor)
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Table 2







n % n %
Hepatitis (% yes) 8 1.6 2 0.5 0.09
Influenza mist (% yes) 98 19.1 20 4.5 <0.01
Influenza injection (% yes) 13 2.5 7 1.6 0.30
Pneumonia** (% yes) 8 1.6 2 0.5 0.09
Herpes Zoster (% yes) 30 5.8 4 0.9 <0.01
Varicella (% yes) 23 4.5 3 0.7 <0.01
MMR*** (% yes) 18 3.5 2 0.5 <0.01
*
chronic immunosuppression defined as current use of biologic or immunomodulator (thiopurine, calcineurin inhibitor, methotrexate)
**
Self-reported receipt of pneumonia vaccine (no data on whether 23-valent or 13-valent vaccine administered)
***
Measles, mumps, rubella





























me due to my
IBD
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Yes No Don’t Know
(Q4120) Hepatitis B ○ ○ ○
(Q4160) Hepatitis A ○ ○ ○
(Q4240) Varicella (chicken pox) ○ ○ ○
(Q4320) Pneumococcal (pneumonia) ○ ○ ○
(Q4360) Influenza (regular flu or swine flu) ○ ○ ○
(Q4400) Meningococcal (meningitis) ○ ○ ○
(Q4200) HPV (cervical cancer and genital warts) ○ ○ ○
(Q4280) Zoster (Shingles) ○ ○ ○
(Q11060) Tetanus ○ ○ ○
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